A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will assess the efficacy and safety of Tarceva plus gemcitabine, compared
with gemcitabine alone, in the treatment of chemotherapy-naive patients with advanced
non-small cell lung cancer. Patients will be randomized to receive either Tarceva 150mg po
daily plus gemcitabine on days 1, 8, 15 and every 4 weeks subsequently, or with gemcitabine
monotherapy. The anticipated time on study treatment is until disease progression, and the
target sample size is 100-500 individuals.